Abstract: An apparatus and computerized method classify a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD). A computing device having an input/output interface, one or more processors and a memory is provided. A total kidney volume (TKV), a patient height, and a patient age for the patient is received via the input/output interface. A height adjusted TKV (HtTKV) is determined based on the total kidney volume and the patient height using the one or more processors. An ADPKD classification for the patient is determined based on the height adjusted TKV and the patient age using the one or more processors. The ADPKD classification is provided for the patient via the input/output interface.

Abstract: An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.

Abstract: An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.

Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.

Abstract: An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.

Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.

Abstract: Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided.

Abstract: Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided.

Abstract: Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided.

Abstract: Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided.